高级检索
当前位置: 首页 > 详情页

Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis

文献详情

资源类型:
Pubmed体系:

收录情况: ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越:领军期刊

机构: [1]Lung Cancer Center/Lung Cancer Institute, West China Hospital & West China School of Pharmacy, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan University, Chengdu 610065, China. [2]Department of Gastrointestinal Surgery, Chengdu Second People's Hospital, Chengdu 610065, China. [3]Laboratory of Infectious Diseases and Vaccine, West China Hospital, Sichuan University, Chengdu 610065, China.
出处:
ISSN:

关键词: Biomimetic nanoparticles Cancer metastasis Tumor microenvironment Immune system Immune cell membrane Tumor-homing Biocompatibility

摘要:
Metastasis is the leading cause of cancer-related death. Despite extensive treatment, the prognosis for patients with metastatic cancer remains poor. In addition to conventional surgical resection, radiotherapy, immunotherapy, chemotherapy, and targeted therapy, various nanobiomaterials have attracted attention for their enhanced antitumor performance and low off-target effects. However, nanomedicines exhibit certain limitations in clinical applications, such as rapid clearance from the body, low biological stability, and poor targeting ability. Biomimetic methods utilize the natural biomembrane to mimic or hybridize nanoparticles and circumvent some of these limitations. Considering the involvement of immune cells in the tumor microenvironment of the metastatic cascade, biomimetic methods using immune cell membranes have been proposed with unique tumor-homing ability and high biocompatibility. In this review, we explore the impact of immune cells on various processes of tumor metastasis. Furthermore, we summarize the synthesis and applications of immune cell membrane-based nanocarriers increasing therapeutic efficacy against cancer metastases via immune evasion, prolonged circulation, enhanced tumor accumulation, and immunosuppression of the tumor microenvironment. Moreover, we describe the prospects and existing challenges in clinical translation.© 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 1 区 医学
小类 | 1 区 药学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 药学
第一作者:
第一作者机构: [1]Lung Cancer Center/Lung Cancer Institute, West China Hospital & West China School of Pharmacy, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan University, Chengdu 610065, China.
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号